Suppository and composition comprising at least one polyethylene glycol
First Claim
1. Suppository for administration of at least one bioactive substance, said suppository comprisingi) a polymer composition comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable;
- and ii) a controlled release formulation for controlled release of said at least one bioactive substance, said formulation comprising at least one biodegradable polymer; and
wherein the suppository essentially does not swell when contacted with an aqueous fluid.
1 Assignment
0 Petitions
Accused Products
Abstract
There is provided a suppository comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable, and wherein the suppository essentially does not swell when contacted with an aqueous fluid. The suppository may further comprise a plurality of open cells at least partly separated from one another by an interpenetrating matrix comprising at least one biocompatible polymer in branched or crosslinked form. The plurality of interlinked, open cells are capable of containing an aqueous fluid, and the permeability of the suppository ensures that entry of body fluids into the open cells under practical circumstances occurs essentially without dehydration of mucousal membrane tissue contacting the suppository. The suppository furthermore preferably comprises a controlled release formulation.
150 Citations
155 Claims
-
1. Suppository for administration of at least one bioactive substance, said suppository comprising
i) a polymer composition comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable; - and
ii) a controlled release formulation for controlled release of said at least one bioactive substance, said formulation comprising at least one biodegradable polymer; and
wherein the suppository essentially does not swell when contacted with an aqueous fluid. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)
i) providing at least one monomeric reagent suitable for polymerization, ii) polymerising said at least one monomeric reagent and obtaining a biocompatible polymer which is essentially non-biodegradable, iii) providing a controlled release formulation for controlled release of at least one bioactive substance, iv) mixing the controlled release formulation and the at least one bioactive substance, and v) shaping the essentially non-biodegradable, biocompatible polymer and the mixture of the controlled release formulation and the at least one bioactive substance into a shape desirable for a suppository. -
72. Method according to claim 71, wherein the suppository is shaped by injection moulding into a predetermined shape.
-
73. Method of claim 71, wherein the monomeric reagents used for obtaining the essentially non-biodegradable, biocompatible polymer comprise at least one polyisocyanate and at least one polyo.
-
74. Suppository obtainable by the method of claim 71.
-
75. Method for alleviating pain in an individual in need thereof, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises the bioactive substance in an amount effective to achieve said pain alleviation in said individual.
-
76. A method for diagnosing a clinical indication in an individual comprising the steps of bringing a suppository according to claim 1 into contact with body tissue of a body cavity an animal, wherein the suppository comprises a diagnostically active substance in an amount effective to achieve said diagnosis.
-
77. A cosmetic method comprising the steps of bringing a suppository according to claim 1 into contact with body tissue of a body cavity of an animal, wherein the suppository comprises a cosmetically active substance in an amount sufficient to achieve a desirable cosmetic effect.
-
78. The suppository of claim 33, where the controlled release formulation comprises
(a) a biodegradable polyethylene glycol with a molecular weight of between 100 and 1500, and (b) a biodegradable polyethylene glycol with a molecular weight of between 1500 and 10,000. -
79. The suppository of claim 33, where the controlled release formulation comprises
(a) a biodegradable polyethylene glycol with a molecular weight of between 400 and 1000, and (b) a biodegradable polyethylene glycol with a molecular weight of more than 1000. -
80. The suppository of claim 79 where PEG (b) has a molecular weight of not more than 35,000.
-
81. The suppository of claim 33 where at least two of the biodegradable polymers of said controlled release formulation differ in melting point from each other.
-
82. The suppository of claim 81 where the ratio of the lowest melting point biodegradable polymer to the highest melting point polymer of said controlled release formulation is about 3:
- 1.
-
83. Method of claim 75, wherein the bioactive substance is selected from the group consisting of analgesics, anaesthetics and antipyretics.
-
84. Method of claim 75, wherein the bioactive substance is selected from opioid analgesics, non-opioid analgesics, and lidocaine, and antiepileptics used to alleviate pain.
-
85. Method of claim 75, wherein the bioactive substance is selected from lidocaine, codeine, morphine, acetaminophen, aspirin, and ibuprofen.
-
86. Method of claim 75, wherein the body tissue is a rnucosal surface.
-
87. Method of claim 86, wherein the mucosal surface is a mucosal surface of the rectum.
-
88. Method of claim 87, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
89. Method of claim 75, wherein the individual is a human being.
-
90. In a method for surgical treatment of ruptured colon in an individual, the improvement comprising alleviating pain by performing the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an analgesic bioactive substance or an anaesthetic bioactive substance in an amount effective to achieve said pain alleviation in said individual.
-
91. Method of claim 90, wherein the body tissue is a mucosal surface.
-
92. Method of claim 91, wherein the mucosal surface is a mucosal surface of the rectum.
-
93. Method of claim 92, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
94. Method of claim 90, wherein the individual is a human being.
-
95. In a method for rectal surgery performed on an individual, the improvement comprising alleviating pain by performing the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an analgesic bioactive substance or an anaesthetic bioactive substance in an amount effective to achieve said pain alleviation in said individual.
-
96. Method of claim 95, wherein the body tissue is a mucosal surface.
-
97. Method of claim 96, wherein the mucosal surface is a mucosal surface of the rectum.
-
98. Method of claim 97, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
99. Method of claim 95, wherein the individual is a human being.
-
100. In a method for surgical treatment of haemorrhoids in an individual, the improvement comprising alleviating pain by performing the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an analgetic bioactive substance or an anaesthetic bioactive substance in an amount effective to achieve said pain alleviation in said individual.
-
101. Method of claim 100, wherein the body tissue is a mucosal surface.
-
102. Method of claim 101, wherein the mucosal surface is a mucosal surface of the rectum.
-
103. Method of claim 102, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
104. Method of claim 100, wherein the individual is a human being.
-
105. In a method for surgical treatment of ruptured vagina of a female mammal, the improvement comprising alleviating pain by performing the steps of contacting a mucosal surface of the vagina of the female mammal with the suppository of claim 1, wherein the suppository comprises an analgetic bioactive substance or an anaesthetic bioactive substance in an amount effective to achieve said pain alleviation in said female mammal.
-
106. Method of claim 105, wherein the mammal is a human being.
-
107. A method for treating an inflammatory condition in an individual, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an anti-inflammatory bioactive substance in an amount effective in treating said inflammatory condition.
-
108. Method of claim 107, wherein the body tissue is a mucosal surface.
-
109. Method of claim 108, wherein the mucosal surface is a mucosal surface of the rectum.
-
110. Method of claim 109, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
111. Method of claim 107, wherein the individual is a human being.
-
112. Method of claim 107, wherein the anti-inflammatory bioactive substance is selected from the group consisting of naproxyn, diclofenac, indomethacin, ibuprofen, acetaminophen, aspirin, and sulindac.
-
113. Method of claim 107, wherein the anti-inflammatory bioactive substance is selected from the group consisting of hydrocortisone, triamcinolone, prednisone, cortisone acetate, prednisolone, methyl prednisolone and dexamethasone.
-
114. Method for treating an infection in an individual, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an anti-infective bioactive substance in an amount effective in treating said infection.
-
115. Method of claim 114, wherein the body tissue is a mucosal surface.
-
116. Method of claim 115, wherein the mucosal surface is a mucosal surface of the rectum.
-
117. Method of claim 116, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
118. Method of claim 114, wherein the individual is a human being.
-
119. Method of claim 114, wherein the anti-infective bioactive substance is selected from the group consisting of anti-biotics, anti-fungals, anti-virals, and anti-septics and anti-protozoans.
-
120. Method of claim 114, wherein the anti-biotic is selected from the group consisting of penicillins, cephalosporins, tetracyclines, ampicillin, aureothicin, bacitracin, chioramphenicol, cycloserine, erythromycin, gentamicin, gramacidin, kanamycin, neomycin, streptomycin, tobramycin, vancomycin, and metronidazole.
-
121. Method of claim 114, wherein the anti-biotic is a beta-lactam antibiotic selected from the group consisting of sulbenicillin, mecillinam, carbenicillin, piperacillin, ticarcillin, and thienamycin.
-
122. Method of claim 114, wherein the anti-biotic is a cephalosporin selected from the group consisting of cefotiam, cefsulodine, cefmenoxime, cefmetazole, cefazolin, cefotaxime, cefoperazone, ceftizoxime and moxalactam.
-
123. Method of claim 114, wherein the anti-viral bioactive species is acyclovir.
-
124. A method for treating a cancer in an individual, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an anti-cancer bioactive substance in an amount effective in treating said cancer.
-
125. Method of claim 124, wherein the body tissue is a mucosal surface.
-
126. Method of claim 125, wherein the mucosal surface is a mucosal surface of the rectum.
-
127. Method of claim 126, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
128. Method of claim 124, wherein the individual is a human being.
-
129. Method of claim 124, wherein the anti-cancer bioactive substance is selected from the group consisting of antimetabolites, cytotoxic agents and immunomodulators.
-
130. Method of claim 129, wherein the antimetabolites are selected from methotrexate, 5-fluorouracil, cytosine arabinoside(ara-C), 5-azacytidine, 6-mercaptopurine, 6-thioguanine, and fludarabine phosphate.
-
131. Method of claim 129, wherein the cytotoxic agents are selected from taxol, epirubicin, esorubicin, doxorubicin, iodo-doxorubicin, daunorubicin, idarubicin, dactinomycin, bleomycin, mitomycin C, plicamycin, mitoxantrone, vincristine, vinblastine, vindesine, etoposide, and teniposide.
-
132. Method of claim 124, wherein the anti-cancer bioactive substance is selected from the group consisting of 5′
- -fluorouracil, mitomycin, cisplatin, taxol, biteomycins, daunomycins, and methamycins.
-
133. Method for treating a hormone condition in an individual, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises a hormone bioactive substance in an amount effective in treating said deficiency.
-
134. Method of claim 133, wherein the body tissue is a mucosal surface.
-
135. Method of claim 134, wherein the mucosal surface is a mucosal surface of the rectum.
-
136. Method of claim 135, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
137. Method of claim 133, wherein the individual is a human being.
-
138. Method of claim 133, wherein the hormone is selected from growth hormone, tPA (tissue plasminogen activator), prolactin, adrenocorticotrophic hormone, melanocyte stimulating hormone, thyrotropin releasing hormone, thyroid stimulating hormone, thyroxine, luteinizing hormone, follicle stimulating hormone, vasopressin, oxytocin, calcitonin, parathyroid hormone, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human placental lactogen, human chorionic gonadotropin, enkephalin, endorphin, insulin, alpha interferon, beta interferon, and gamma interferon.
-
139. Method of claim 133, wherein the hormone is selected from corticosteriods, estrogens, progestins, antiestrogens, aromastase inhibitors, androgens, antiandrogens, and endocrines for prostate cancer.
-
140. Method of claim 133, wherein the hormone is selected from cortisone acetate, hydrocortisone, prednisone, prednisolone, methyl prednisolone and dexamethasone, diethyistibesterol, estradiol, esterified estrogens, conjugated estrogen, chiorotiasnene, medroxyprogesterone acetate, hydroxy progesterone caproate, megestrol acetate, tamoxifen, aminoglutethimide, testosterone propionate, methyltestosterone, fluoxymesterone, testolactone, flutamide, leuprolide acetate, and ketoconazole.
-
141. A method for contraception comprising the steps of contacting body tissue of a body cavity of a female mammal with the suppository of claim 1, wherein the suppository comprises a contraceptive bioactive substance in an amount effective to achieve said contraception in said female mammal.
-
142. Method of claim 141, wherein the body tissue is a mucosal surface.
-
143. Method of claim 142, wherein the mucosal surface is a mucosal surface of the vagina.
-
144. Method of claim 141, wherein the mammal is a human being.
-
145. A surgical method performed on an individual, comprising modifying blood coagulation by performing the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises a coagulation modifying agent in an amount effective to achieve said blood coagulation modification.
-
146. Method of claim 145, wherein the body tissue is a mucosal surface.
-
147. Method of claim 146, wherein the mucosal surface is a mucosal surface of the rectum.
-
148. Method of claim 147, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
149. Method of claim 145, wherein the individual is a human being.
-
150. Method for immunising an individual, said method comprising the steps of contacting body tissue of a body cavity of the individual with the suppository of claim 1, wherein the suppository comprises an antigenic substance in an amount effective in achieving said immunisation.
-
151. Method of claim 150, wherein the body tissue is a mucosal surface.
-
152. Method of claim 151, wherein the mucosal surface is a mucosal surface of the rectum.
-
153. Method of claim 152, wherein the mucosal surface of the rectum is the surface located below the caudal semilunary fold.
-
154. Method of claim 150, wherein the individual is a human being.
-
155. Method of claim 150, wherein the suppository further comprises an adjuvant.
- and
Specification